Finally, a pediatric-specific treatment
for adrenal insufficiency

Introducing ALKINDI SPRINKLE, the first and only FDA-approved hydrocortisone granules that allow for more accurate and individualized dosing in your smallest patients1,2

ALKINDI SPRINKLE flexible dosing options for hydrocortisone

Capsules for opening

First granular pediatric-specific adrenal insufficiency treatment ever

ALKINDI SPRINKLE is a granular formulation of hydrocortisone therapy that is indicated for all forms of adrenal insufficiency (AI)—including congenital adrenal hyperplasia (CAH)—in infants, children, and adolescents (neonate to <17 years old).1*

ALKINDI SPRINKLE Patient Referral Form icon

Get your patients started today!

Complete the ALKINDI SPRINKLE Patient Referral Form and send via fax (855-813-2039) to AnovoRx to enroll your patient in the Eton Cares Program.

Download

IFU=instructions for use.

*The safety and effectiveness of ALKINDI SPRINKLE have not been established in patients over 17 years of age.1

References:

  • ALKINDI SPRINKLE. Package insert. Eton Pharmaceuticals, Inc; 2020.
  • Whitaker MJ, Spielmann S, Digweed D, et al. Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency. J Clin Endocrinol Metab. 2015;100(4):1681-1688. doi:10.1210/jc.2014-4060.

Be the first to know

Sign up to receive the latest updates and information about ALKINDI SPRINKLE.

Eton Pharmaceuticals logo

This site is for US audiences only. © 2020 Eton Pharmaceuticals. All rights reserved. Eton, ALKINDI SPRINKLE, and Eton Cares are trademarks of Eton Pharmaceuticals. All other trademarks are property of their respective owners. WS-ALK-001-rev1-11/20